195 related articles for article (PubMed ID: 37995313)
1. Real-World Outcomes of Trastuzumab Deruxtecan in Patients With HER2+ Metastatic Breast Cancer: The DE-REAL Study.
Botticelli A; Caputo R; Scagnoli S; Pisegna S; De Laurentiis M; Curigliano G; Lambertini M; Pantano F; Palazzo A; Paris I; Vernieri C; Tedesco B; Giampaglia M; Palleschi M; Ballatore Z; Alesini D; D'Auria G; Fabbri A; Rossi L; Verrazzo A; Scafetta R; Marinelli D; Sposetti C; Barberi V; Strigari L; Marchetti P; Santini D; Fabi A
Oncologist; 2024 Apr; 29(4):303-310. PubMed ID: 37995313
[TBL] [Abstract][Full Text] [Related]
2. Optimizing treatment management of trastuzumab deruxtecan in clinical practice of breast cancer.
Rugo HS; Bianchini G; Cortes J; Henning JW; Untch M
ESMO Open; 2022 Aug; 7(4):100553. PubMed ID: 35964548
[TBL] [Abstract][Full Text] [Related]
3. Trastuzumab deruxtecan in previously treated patients with HER2-positive metastatic breast cancer: updated survival results from a phase II trial (DESTINY-Breast01).
Saura C; Modi S; Krop I; Park YH; Kim SB; Tamura K; Iwata H; Tsurutani J; Sohn J; Mathias E; Liu Y; Cathcart J; Singh J; Yamashita T
Ann Oncol; 2024 Mar; 35(3):302-307. PubMed ID: 38092229
[TBL] [Abstract][Full Text] [Related]
4. Trastuzumab deruxtecan in previously treated HER2-positive metastatic or unresectable breast cancer: Real-life data from the temporary use authorization program in France.
Petit T; Hajjaji N; Antoine EC; Benderra MA; Gozy M; Foa C; Mouysset JL; Grenier J; Mousseau M; Mailliez A; Saghatchian M; Lachaier E; Desmoulins I; Hennequin A; Maes P; Loirat D; Ricci F; Diéras V; Berton D; Tiong FL; Teixeira L; Dohollou N; Lévy C; Bachelot T; Pierga JY
Cancer Med; 2024 May; 13(9):e7168. PubMed ID: 38733172
[TBL] [Abstract][Full Text] [Related]
5. Trastuzumab deruxtecan versus trastuzumab emtansine in HER2-positive metastatic breast cancer patients with brain metastases from the randomized DESTINY-Breast03 trial.
Hurvitz SA; Kim SB; Chung WP; Im SA; Park YH; Hegg R; Kim MH; Tseng LM; Petry V; Chung CF; Iwata H; Hamilton E; Curigliano G; Xu B; Egorov A; Liu Y; Cathcart J; Bako E; Tecson K; Verma S; Cortés J
ESMO Open; 2024 May; 9(5):102924. PubMed ID: 38796287
[TBL] [Abstract][Full Text] [Related]
6. Antitumor Activity and Safety of Trastuzumab Deruxtecan in Patients With HER2-Low-Expressing Advanced Breast Cancer: Results From a Phase Ib Study.
Modi S; Park H; Murthy RK; Iwata H; Tamura K; Tsurutani J; Moreno-Aspitia A; Doi T; Sagara Y; Redfern C; Krop IE; Lee C; Fujisaki Y; Sugihara M; Zhang L; Shahidi J; Takahashi S
J Clin Oncol; 2020 Jun; 38(17):1887-1896. PubMed ID: 32058843
[TBL] [Abstract][Full Text] [Related]
7. Clinical Practices and Institutional Protocols on Prophylaxis, Monitoring, and Management of Selected Adverse Events Associated with Trastuzumab Deruxtecan.
Bardia A; Harnden K; Mauro L; Pennisi A; Armitage M; Soliman H
Oncologist; 2022 Aug; 27(8):637-645. PubMed ID: 35642907
[TBL] [Abstract][Full Text] [Related]
8. Trastuzumab deruxtecan in previously treated HER2-positive metastatic breast cancer: Plain language summary of the DESTINY-Breast01 study.
Modi S
Future Oncol; 2021 Sep; 17(26):3415-3423. PubMed ID: 34263665
[TBL] [Abstract][Full Text] [Related]
9. Impacts of clinicopathological factors on efficacy of trastuzumab deruxtecan in patients with HER2-positive metastatic breast cancer.
Nakajima H; Harano K; Nakai T; Kusuhara S; Nakao T; Funasaka C; Kondoh C; Matsubara N; Naito Y; Hosono A; Mitsunaga S; Ishii G; Mukohara T
Breast; 2022 Feb; 61():136-144. PubMed ID: 34999427
[TBL] [Abstract][Full Text] [Related]
10. Analysis of Adverse Events Associated with Trastuzumab Deruxtecan in Patients with Gastric and Breast Cancer: A Retrospective Study.
Nonomiya Y; Nakayama I; Kobayashi K; Amakawa Y; Shibata N; Soejima A; Kawakami K; Shimizu H; Takahari D; Kawai S; Hara F; Takano T; Yamaguchi K; Yamaguchi M
Biol Pharm Bull; 2024; 47(2):411-416. PubMed ID: 38346748
[TBL] [Abstract][Full Text] [Related]
11. Exposure-Response Relationships in Patients With HER2-Positive Metastatic Breast Cancer and Other Solid Tumors Treated With Trastuzumab Deruxtecan.
Yin O; Iwata H; Lin CC; Tamura K; Watanabe J; Wada R; Kastrissios H; AbuTarif M; Garimella T; Lee C; Zhang L; Shahidi J; LaCreta F
Clin Pharmacol Ther; 2021 Oct; 110(4):986-996. PubMed ID: 33999422
[TBL] [Abstract][Full Text] [Related]
12. Trastuzumab deruxtecan for HER2+ advanced breast cancer.
Lee J; Park YH
Future Oncol; 2022 Jan; 18(1):7-19. PubMed ID: 34823373
[TBL] [Abstract][Full Text] [Related]
13. A Review of Fam-Trastuzumab Deruxtecan-nxki in HER2-Positive Breast Cancer.
Nguyen X; Hooper M; Borlagdan JP; Palumbo A
Ann Pharmacother; 2021 Nov; 55(11):1410-1418. PubMed ID: 33629601
[TBL] [Abstract][Full Text] [Related]
14. Trastuzumab deruxtecan in patients with central nervous system involvement from HER2-positive breast cancer: The DEBBRAH trial.
Pérez-García JM; Vaz Batista M; Cortez P; Ruiz-Borrego M; Cejalvo JM; de la Haba-Rodriguez J; Garrigós L; Racca F; Servitja S; Blanch S; Gion M; Nave M; Fernández-Abad M; Martinez-Bueno A; Llombart-Cussac A; Sampayo-Cordero M; Malfettone A; Cortés J; Braga S
Neuro Oncol; 2023 Jan; 25(1):157-166. PubMed ID: 35639825
[TBL] [Abstract][Full Text] [Related]
15. Neoadjuvant trastuzumab deruxtecan (T-DXd) with response-directed definitive therapy in early stage HER2-positive breast cancer: a phase II study protocol (SHAMROCK study).
Dowling GP; Toomey S; Bredin P; Parker I; Mulroe E; Marron J; McLoughlin O; Teiserskiene A; Power C; O'Shea AM; Greally M; Morris PG; Duke D; Hill ADK; Hennessy BT
BMC Cancer; 2024 Jan; 24(1):91. PubMed ID: 38233810
[TBL] [Abstract][Full Text] [Related]
16. A real-world study of treatment sequences and second-line clinical outcomes in patients with HER2-positive metastatic breast cancer in US community practice.
Varghese D; Cruz GI; Johanson C; Toland L; Miranda M; Faherty EC; Harland D; Kaplan HG
Int J Clin Oncol; 2024 Jun; 29(6):780-789. PubMed ID: 38528295
[TBL] [Abstract][Full Text] [Related]
17. [Chinese expert consensus on the management of clinical pathway and adverse events of trastuzumab deruxtecan (2024 edition)].
Trastuzumab Deruxtecan Clinical Management Pathway and Adverse Reaction Management Consensus Expert Group
Zhonghua Zhong Liu Za Zhi; 2024 Apr; 46(4):304-318. PubMed ID: 38644266
[TBL] [Abstract][Full Text] [Related]
18. Efficacy and Safety of Trastuzumab Deruxtecan in Breast Cancer: A Systematic Review and Meta-Analysis.
Dowling GP; Daly GR; Keelan S; Boland F; Toomey S; Hill ADK; Hennessy BT
Clin Breast Cancer; 2023 Dec; 23(8):847-855.e2. PubMed ID: 37775347
[TBL] [Abstract][Full Text] [Related]
19. Trastuzumab deruxtecan in patients with metastatic non-small-cell lung cancer (DESTINY-Lung01): primary results of the HER2-overexpressing cohorts from a single-arm, phase 2 trial.
Smit EF; Felip E; Uprety D; Nagasaka M; Nakagawa K; Paz-Ares Rodríguez L; Pacheco JM; Li BT; Planchard D; Baik C; Goto Y; Murakami H; Saltos A; Pereira K; Taguchi A; Cheng Y; Yan Q; Feng W; Tsuchihashi Z; Jänne PA
Lancet Oncol; 2024 Apr; 25(4):439-454. PubMed ID: 38547891
[TBL] [Abstract][Full Text] [Related]
20. Efficacy and Safety of Trastuzumab Deruxtecan in Patients With HER2-Expressing Solid Tumors: Primary Results From the DESTINY-PanTumor02 Phase II Trial.
Meric-Bernstam F; Makker V; Oaknin A; Oh DY; Banerjee S; González-Martín A; Jung KH; Ługowska I; Manso L; Manzano A; Melichar B; Siena S; Stroyakovskiy D; Fielding A; Ma Y; Puvvada S; Shire N; Lee JY
J Clin Oncol; 2024 Jan; 42(1):47-58. PubMed ID: 37870536
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]